Development of ROR ligands for treatment of circadian rhythm disorders

开发用于治疗昼夜节律紊乱的 ROR 配体

• 批准号: 8209001
• 负责人: Thomas P Burris
• 金额: $ 74.44万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-12-22 至 2014-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8209001
• 关键词: Address; Animals; Biological Assay; Bipolar Disorder; Chemicals; Circadian Dysregulation; Circadian Rhythms; Data; Development; Disease; Drug Delivery Systems; Drug Kinetics; Goals; Health; Human; Immune response; Lead; Ligands; Mental Depression; Metabolism; Mus; Neuraxis; Nuclear Hormone Receptors; Orphan; Pathologic Processes; Pathology; Pathway interactions; Pharmaceutical Preparations; Pharmacodynamics; Pharmacology; Physiological; Physiological Processes; Property; Psychotic Disorders; RORA gene; Regulation; Research; Retinoic Acid Receptor; Role; Scheme; Schizophrenia; Sleep Disorders; Source; Structure-Activity Relationship; Synthesis Chemistry; Testing; base; design; human disease; improved; in vivo; innovation; mRNA Expression; member; nervous system disorder; novel; public health relevance; receptor; scaffold; tool; transcription factor

DESCRIPTION (provided by applicant): The nuclear hormone receptor superfamily (NHR) and ligand regulated transcription factors that have proven to be a rich source of targets for development of drugs that target myriad human diseases. The retinoic acid receptor-related orphan receptors (RORs) are members of this superfamily and regulate several physiological processes including the circadian rhythm, metabolism and the immune response. We recently identified the first selective synthetic ligands that target ROR, a critical regulator of the circadian rhythm. Our long-term goal is to develop ligands targeting RORs that can be used to treat diseases associated with dysregulation of the circadian rhythm such as bipolar and sleep disorders as well as schizophrenia. The initial lead compound (T0901317) has less than optimal properties for use as a drug targeting ROR and our preliminary data indicates that we can significantly improve its drug like properties. We hypothesize that optimized ROR ligands, based on the T0901317 chemical scaffold, with improved pharmacodynamic, pharmacokinetic, and receptor selectivity properties will have efficacy in modulation of the circadian rhythm. In order to address this hypothesis we will focus on the following specific aims: 1) Develop and optimize ROR ligands with improved pharmacokinetic and pharmacodynamic properties targeting the central nervous system; 2) Characterize the actions of ROR ligands on the circadian rhythm in animals. We predict that this research will provide novel, innovative ligands that modulate ROR1 activity that will have potential utility to treat sleep disorders as well as other disorders associated with dysregulation of the circadian rhythm including biopolar disorder and schizophrenia. PUBLIC HEALTH RELEVANCE: The nuclear hormone receptor superfamily (NHR) has proven to be a rich source of targets for development of drugs that target myriad human diseases and we recently identified the first selective synthetic ligands for the retinoic acid receptor-related orphan receptors (RORs). This receptor is a key regulator of the circadian rhythm and dysregulation of the circadian rhythm is associated with several disorders of the nervous system including bipolar and sleep disorders. The goal of this proposal is to develop ROR ligands with optimized pharmacodynamic and pharmacokinetic properties and appropriate receptor selectivity profiles that we will evaluate for their ability to modulate circadian function in vivo.

描述（由申请人提供）：核激素受体超家族（NHR）和配体调节转录因子已被证明是开发针对多种人类疾病的药物的丰富靶标来源。视黄酸受体相关孤儿受体 (ROR) 是该超家族的成员，调节多种生理过程，包括昼夜节律、新陈代谢和免疫反应。我们最近发现了第一个针对 ROR 的选择性合成配体，ROR 是昼夜节律的关键调节因子。我们的长期目标是开发针对 ROR 的配体，可用于治疗与昼夜节律失调相关的疾病，例如双相情感障碍、睡眠障碍以及精神分裂症。最初的先导化合物 (T0901317) 作为 ROR 靶向药物的性能不太理想，我们的初步数据表明我们可以显着改善其类似药物的性能。我们假设基于 T0901317 化学支架的优化 ROR 配体具有改善的药效学、药代动力学和受体选择性特性，将有效调节昼夜节律。为了解决这一假设，我们将重点关注以下具体目标：1）开发和优化 ROR 配体，以改善针对中枢神经系统的药代动力学和药效学特性； 2) 表征 ROR 配体对动物昼夜节律的作用。我们预测这项研究将提供调节 ROR1 活性的新型配体，这些配体将具有治疗睡眠障碍以及与昼夜节律失调相关的其他疾病（包括双向情感障碍和精神分裂症）的潜在用途。 公共卫生相关性：核激素受体超家族 (NHR) 已被证明是开发针对多种人类疾病的药物的丰富靶标来源，我们最近确定了第一个选择性合成配体，用于视黄酸受体相关孤儿受体 (ROR) ）。该受体是昼夜节律的关键调节剂，昼夜节律失调与包括躁郁症和睡眠障碍在内的多种神经系统疾病有关。该提案的目标是开发具有优化的药效和药代动力学特性以及适当的受体选择性特征的 ROR 配体，我们将评估它们调节体内昼夜节律功能的能力。